While uncertainties underlay the significant uncertainty on the ACE1/ACE2 receptor ratio, there has been no increase in the ACE2 receptor with the use of ACEi and no measurable increased risk with ARB [81]. There are no clinically significant findings that any RAAS-inhibiting drugs should be discontinued or limited in any way but further longitudinal studies with a comprehensive analysis should be considered in future studies, as they are effective in the treatment of hypokalemia in hypertensive COVID-19 patients [89,94]. The gene discussed is ACE; the disease is COVID-19.